Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
YH-013 by Eucure (Beijing) Biopharma for Metastatic Pancreatic Cancer: Likelihood of Approval
YH-013 is under clinical development by Eucure (Beijing) Biopharma and currently in Phase I for Metastatic Pancreatic Cancer. According to...
YH-013 by Eucure (Beijing) Biopharma for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
YH-013 is under clinical development by Eucure (Beijing) Biopharma and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According...
YH-013 by Eucure (Beijing) Biopharma for Metastatic Colorectal Cancer: Likelihood of Approval
YH-013 is under clinical development by Eucure (Beijing) Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to...